|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
IgHV1-69 is one of the most frequently rearranged IgHV genes in CLL and the majority of IgHV1-69 cases lack somatic hypermutation and display poor prognosis.
|
18398745 |
2008 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
It was showed that LPL expression correlates with IgVH mutational status and other clinical or laboratory prognostic factors, and might be applied for the assessment of prognosis in patients with CLL.
|
18616755 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The correlation between well-established biological parameters of prognostic relevance in B-cell chronic lymphocytic leukaemia (CLL) [i.e., mutational status of the immunoglobulin heavy chain variable region (IgV(H)), ZAP-70- and CD38-expression] and adiponectin serum concentration was evaluated in a cohort of 69 previously untreated Binet stage A CLL patients.
|
18818986 |
2008 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
For patients with mutated IGHV genes, reduced kappa/lambda ratios were adversely prognostic and associated with the poor prognostic IGHV3-21, IGHV3-48 and IGHV3-53 subgroups, suggesting an abnormal sFLC ratio may reflect biological subgroups within CLL.
|
19016722 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Simultaneous analysis of ZAP-70, CD38 and IGHV mutations in CLL provides more discriminatory prediction of TFI than any factor alone.
|
19021053 |
2008 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed IGHV-D-J rearrangements in 51 CLL-like MBL cases from healthy individuals, characterized by few clonal B cells.
|
19029437 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Regarding clinical outcome: (i) UM CLL from the IGHV1-2/1-3/1-18/1-46/7-4-1/IGKV1-39 cluster had poorer prognosis than UM/M cases, or UM cases using the same IGHV genes but not in clusters; (ii) M CLL from the IGHV3-21/IGLV3-21 cluster had TTT similar to UM CLL, and shorter than M CLL expressing IGHV3-21 but not in cluster.
|
19036101 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Most investigated drugs demonstrated similar activity in CLL cells from patients with unmutated and mutated IGHV genes as well as in CLL cells vs. PBMC.
|
19245531 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
|
19340428 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
CLL samples were used for characterisation of the mutational status of BCL6/ immunoglobulin variable heavy chain (IGHV) genes, and expression of BCL6 was determined by real time PCR and immunoblot.
|
19367498 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
IGHV mutational status and ZAP-70 or CD38 expression correlate with clinical course in B-cell chronic lymphocytic leukaemia (CLL).
|
19438486 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
It was showed that serum TK1 concentration could be a predictive marker of IGHV mutational status, and might be applied for the assessment of prognosis in patients with CLL.
|
19629630 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Finally, LPL protein expression correlated significantly with mRNA expression and was higher in IGHV unmutated versus mutated CLL (p=0.018), although the majority of synthesized protein was catalytically inactive indicating a non-catalytical function in CLL.
|
19709746 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
To address this issue, we conducted a large-scale subcloning study of rearranged immunoglobulin heavy variable (IGHV) genes of diverse mutational status from 71 CLL cases (total, 1496 subcloned sequences), belonging to both the common IgM/IgD variant and the rare IgG-positive variant.
|
19713457 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Chromosomal abnormalities, immunoglobulin heavy chain variable-region (IGHV) gene mutation status, and zeta-associated protein 70 (ZAP-70) expression levels have independent prognostic relevance in chronic lymphocytic leukemia (CLL); however, their concordance is variable.
|
19717645 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Studies of familial CLL have suggested that the disease features are largely similar to sporadic CLL, although recent data suggest that familial CLL may more commonly show somatic hypermutation of the immunoglobulin heavy-chain variable region, suggesting a more indolent disease course.
|
19802369 |
2008 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
The most frequently used IGHV gene was IGHV3-7 (12.6%) followed by IGHV3-30 (11.4%), IGHV3-48 (9.2%), IGHV4-39 (6.9%), and IGHV1-8 (6.9%) genes, which taken together comprised nearly half of the IGHV genes expressed in the Iranian CLL patients.
|
19824994 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In comparison with patients using alternative immunoglobulin heavy-chain variable (IGHV) genes, patients with IgHV1-69 CLLs more often presented at advanced stage, lacked somatic hypermutation (unmutated cases, 87% vs. 35%; P = .00001), and expressed unfavorable biologic characteristics.
|
19858060 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
A higher TCL1 expression level was detected in patients with CLL with unmutated vs. mutated IGHV genes (P < 0.001), whereas no difference was demonstrated within the IGHV3-21 cohort (i.e., mutated vs. unmutated and stereotyped vs. non-stereotyped complementarity determining region 3).
|
19889012 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
IGHV3-23 was the second most frequently used (134 of 1,426) and usually mutated (M; 109 of 134) IGHV gene in our CLL series.
|
20068100 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Increasing evidence supports the prognostic relevance of specific immunoglobulin heavy chain variable (IGHV) genes or stereotyped B-cell receptors (BCR) in chronic lymphocytic leukemia (CLL).
|
20068107 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Interestingly, high binding to MEACs significantly correlated with poor patient survival, suggesting that the basis of IGHV mutation status as a CLL prognostic factor reflects antigen binding.
|
20110421 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis.
|
20110453 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Mutational status of the immunoglobulin variable heavy chain region (IGHV) gene stratifies CLL patients into two prognostic groups.
|
20228263 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
A fraction of chronic lymphocytic leukemia (CLL) carries highly homologous B-cell receptors, characterized by non-random combinations of immunoglobulin heavy-chain variable (IGHV) genes and heavy-chain complementarity-determining region-3 (HCDR3), often associated with a restricted selection of IG(K/L)V light chains.
|
20233059 |
2010 |